The Effect of Lumbar CSF Drainage on the Neurologic Outcome Improvement in OHCA Underwent TTM
NCT ID: NCT04328974
Last Updated: 2024-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2021-07-05
2024-01-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: This is a prospective single-center study conducted from May 2020 to November 2021 on patients who have been treated with TTM following CA. The propensity score matching is proceeded between the lumbar CSF drainage and non-lumbar CSF drainage groups. The good outcome group is defined as a Glasgow-Pittsburgh cerebral performance categories (CPC) scale 1 or 2, and the poor outcome group as a CPC between 3 and 5. Lumbar CSF drainage is initiated when intracranial pressure (ICP) exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP is less than 15 mmHg. The magnetic resonance imaging (MRI) is obtained between 72-96 h after return of spontaneous circulation (ROSC) to evaluate the effect of lumbar CSF drainage on attenuation of brain swelling through quantitative analysis of apparent diffusion coefficient (ADC). Multivariate logistic regression and Kaplan-Meier models are built to identify the effect of CSF drainage on the neurologic outcome improvement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Outcomes Related to Cerebrospinal Fluid Drain Placement
NCT04505423
Efficacy of Lung and Inferior Vena Cava Sonography for Fluid Optimization
NCT05400343
Evaluation of Corrected Carotid Artery Flow Time as a Predictor of Fluid Responsiveness in Spontaneous Breathing Patients
NCT02843477
A Comparison Between Two Techniques for Performing Decompressive Craniectomy
NCT02594137
Predicting Long-term Outcomes After Cardiac Arrest by Using Serum NGAL
NCT03615300
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Several therapeutic approaches have been established for the treatment of increased ICP in traumatic brain injury, including TTM, elevation of the head, sedation, volume resuscitation, maintenance of adequate arterial oxygenation, cerebrospinal fluid drainage via a ventriculostomy, moderate hyperventilation, and mannitol administration. However, despite these various therapies, a considerable number of patients remain nonresponsive to aggressive management strategies. During the last decades, controlled lumbar cerebrospinal fluid (CSF) drainage has been considered to be contraindicated in the setting of increased ICP because of the possibility of transtentorial or tonsillar herniation. In contrast, a recent report on the use of lumbar CSF drainage to treat refractory increased ICP suggested that this controversial therapeutic strategy might be efficient and a valuable treatment when applied to carefully selected patients had discernible basal cisterns and controlled release of CSF under monitoring of ICP and vital signs. Plus, much of the CSF volume is present in the subarachnoid spaces and cisterns around the brain. This CSF is not accessible for drainage by ventriculostomies but is accessible by lumbar drainage.
However, to the best of our knowledge, there is no study on the effect of lumbar CSF drainage to improve neurologic outcome in CA patients treated with TTM. The investigators aim to evaluate the effect of lumbar CSF drainage on neurologic outcome in post-CA patients treated with TTM.
2. Methods: This study was approved by the Institutional Review Board of the Chungnam National University Medical Centre (CNUH IRB 2019-07-033-003). The investigators will obtain approval and consent from the next of kin before enrolment.
2.1. Study design and patients: This is a prospective single-center study conducted from May 2020 to November 2021 on patients who have been treated with TTM following OHCA. The primary endpoint is to measure the effect of the lumbar CSF drainage on the neurologic outcome using the Glasgow-Pittsburgh cerebral performance categories (CPC) scale in post-CA patients treated with TTM. The secondary endpoint is to measure the effect of the lumbar CSF drainage on attenuation of brain edema using MRI in post-CA patients treated with TTM. The data are collected from the electrical medical record. The investigators name the patients are treated with our standard protocol as the non-lumbar CSF drainage group, whereas the patients treated with the protocol and the lumbar CSF drainage are called as the lumbar CSF drainage group. The investigators measure neurological out-comes 6 months after ROSC using CPC scale, either through face-to-face interviews or structured telephone interviews. Phone interviews will be undertaken by an emergency physician who is fully informed of the protocol and blinded to the patient's prognosis. The CPC score classifies patients into 5 categories: CPC 1 (good performance), CPC 2 (moderate disability), CPC 3 (severe disability), CPC 4 (vegetative state), or CPC 5 (brain death or death). The good outcome group is defined as a CPC 1 or 2, and the poor outcome group as a CPC between 3 and 5. Resuscitated cardiac arrest patients whose GCS is 8 or less after ROSC, and who undergo TTM are included in the study. The exclusion criteria for this study are as follows: (1) \< 18 y of age, (2) traumatic CA or interrupted TTM (due to haemodynamic instability), (3) not eligible for TTM (i.e., intracranial haemorrhage, active bleeding, known terminal illness, or poor pre-arrest neurological status), (4) ineligible for LP (i.e., brain computed tomography showed severe cerebral oedema, obliteration of the basal cisterns, occult intracranial mass lesion, antiplatelet therapy, anticoagulation therapy, or coagulopathy: platelet count \< 40 x 103/mL or international normalized ratio (INR) \> 1.5) (5) on extracorporeal membrane oxygenation, (6) there are no next of kin to consent to LP, and (7) refusal of further treatment by the next of kin.
2.2. TTM protocol: TTM is applied using cooling devices (Arctic Sun ® Energy Transfer Pads TM, Medivance Corp., Louisville, USA). The target temperature of 33°C is maintained for 24 h with subsequent rewarming to 37°C at a rate of 0.25°C /h. Temperature is monitored using an esophageal and bladder temperature probe. ADMS™ (Anaesthetic Depth Monitor for Sedation, Unimedics CO., LTD., Seoul, Korea) is used to monitor the anaesthesia depth. Midazolam (0.05 mg/kg intravenous bolus, followed by a titrated intravenous continuous infusion at a dose between 0.05 and 0.2 mg/kg/h) and cisatracurium (0.15 mg/kg intravenous bolus, followed with an infusion of up to 0.3 mg/kg/h) are administered for sedation and control of shivering. Electroencephalography is performed if there is a persistent deterioration of the patient's level of consciousness, involuntary movements, or seizures. If there is evidence of electrographic seizure or a clinical diagnosis of seizure, anti-epileptic drugs are administered; levetiracetam (loading dose 2 g bolus intravenously and maintenance dose, 1 g bolus twice daily, intravenously). Fluid resuscitation or vasopressors are administered when necessary to maintain mean arterial pressure between 85- and 100-mm Hg.
2.3. Data collection: The following data are collected from the database: age, sex, presence of a witness at the time of the collapse, bystander cardiopulmonary resuscitation (CPR), first monitored rhythm, etiology of cardiac arrest, time from collapse to CPR (no flow time), time from CPR to ROSC (low flow time), sequential organ failure assessment (SOF) score, ICP measured on immediate after ROSC, time from ROSC to inserting a lumbar drainage catheter placed through the lumbar vertebral interspace into the subarachnoid space (ICP time), and CPC at 6 months after ROSC.
2.4. ICP control via lumbar CSF drainage: The investigators have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter is inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter is practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies is initiated when ICP exceed 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP is less than 15 mmHg.
2.5. MRI protocol and analysis: The investigators have a standardised magnetic resonance imaging (MRI) protocol for non-traumatic OHCAs. MRI imaging includes diffusion weighted image (DWI), and apparent diffusion coefficient (ADC) map. The MRI is obtained between 72-96 h after ROSC. Forty contiguous DWI sections per patient are acquired using a 3T scanner (Achieva 3 T; Philips Medical System, The Netherlands). The standard of b=1000 s/mm2 is used for all DWIs. ADC maps are created from the mono-exponential calculation of DWI with a commercial software and workstation system (Leonardo MR Workplace; Siemens Medical Solutions, Erlangen, Germany). For quantitative analysis of ADC, images are processed and analysed using software (FMRIB Software Library, Release 5.0 (c) 2012, The University of Oxford) that can extract brain tissue by eliminating cranium, optic structure, and extra-cranial soft tissues. Images are retrieved in Digital Imaging and Communications in Medicine format from picture archiving and communication system servers at the hospital and are converted to NITFI format using MRIcron (http://www.nitrc.org/projects/mricron). ADC thresholds range from 0 to 2200 X 10-6 mm2/s to exclude artefacts or pure CSF. The percentage of voxels (PV) meant voxel number of brain edema is divided by total voxel number.
The % voxels of ADC values (PV):
PV of cytotoxic edema = (Voxel numbers of ADC value ( from 0 to 600 X 10-6 mm2/s))/(Voxel numbers of ADC value (from 0 to 2200 X 10-6 mm2/s))
PV of vasogenic edema = (Voxel numbers of ADC value ( from 1050 to 2200 X 10-6 mm2/s))/(Voxel numbers of ADC value (from 0 to 2200 X 10-6 mm2/s))
2.6. Statistical analysis: The investigators report continuous variables as median with interquartile range or as mean and standard deviation depending on the normal distribution. Categorical variables are reported as frequencies and percentages. The investigators perform the propensity score matching with age, sex, presence of a witness at the time of the collapse, bystander CPR, first monitored rhythm, causes of CA, no flow time, low flow time, sequential organ failure assessment (SOFA) score, and ICP on immediate after ROSC between both groups. Comparisons between the two groups are made using the chi-square test, Fisher's exact test, the Mann-Whitney U test, or two-tailed t-test. Multivariate logistic regression models are built to identify the effect of the lumbar CSF drainage on the neurologic outcome. Kaplan-Meier analysis is performed to evaluate the effect of the lumbar CSF drainage on the neurologic outcome at 6 months after ROSC. The estimated odds ratio is considered to assess risk. All statistical analyses are performed using the PASW/SPSSTM software, version 18 (IBM Inc., Chicago, USA). Results are considered significant at P \< 0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the lumbar CSF drainage group
We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
lumbar CSF drainage
We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lumbar CSF drainage
We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* OHCA patients whose GCS is 8 or less after ROSC
* OHCA patients who undergo TTM
Exclusion Criteria
* Traumatic CA
* Interrupted TTM due to hemodynamic instability
* Intracranial hemorrhage
* Active bleeding
* Known terminal illness
* Poor pre-arrest neurological status
* Brain computed tomography showed severe cerebral edema
* Brain computed tomography showed obliteration of the basal cisterns
* Brain computed tomography showed occult intracranial mass lesion
* Antiplatelet therapy
* Anticoagulation therapy
* Platelet count \< 40,000/mL
* International normalized ratio (INR) \> 1.5
* OHCA patients on extracorporeal membrane oxygenation
* There are no next of kin to consent to LP
* Refusal of further treatment by the next of kin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Research Foundation of Korea
OTHER
Chungnam National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yeonho You, professor
Role: STUDY_DIRECTOR
Chungnam National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungnam National University Hospital
Daejeon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Iida K, Satoh H, Arita K, Nakahara T, Kurisu K, Ohtani M. Delayed hyperemia causing intracranial hypertension after cardiopulmonary resuscitation. Crit Care Med. 1997 Jun;25(6):971-6. doi: 10.1097/00003246-199706000-00013.
Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241.
You Y, Park J, Min J, Yoo I, Jeong W, Cho Y, Ryu S, Lee J, Kim S, Cho S, Oh S, Lee J, Ahn H, Lee B, Lee D, Na K, In Y, Kwack C, Lee J. Relationship between time related serum albumin concentration, optic nerve sheath diameter, cerebrospinal fluid pressure, and neurological prognosis in cardiac arrest survivors. Resuscitation. 2018 Oct;131:42-47. doi: 10.1016/j.resuscitation.2018.08.003. Epub 2018 Aug 4.
Park JS, You Y, Min JH, Yoo I, Jeong W, Cho Y, Ryu S, Lee J, Kim SW, Cho SU, Oh SK, Ahn HJ, Lee J, Lee IH. Study on the timing of severe blood-brain barrier disruption using cerebrospinal fluid-serum albumin quotient in post cardiac arrest patients treated with targeted temperature management. Resuscitation. 2019 Feb;135:118-123. doi: 10.1016/j.resuscitation.2018.10.026. Epub 2018 Oct 26.
Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, Rubiano AM, Shutter L, Tasker RC, Vavilala MS, Wilberger J, Wright DW, Ghajar J. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017 Jan 1;80(1):6-15. doi: 10.1227/NEU.0000000000001432.
Cushing H. Some aspects of the pathological physiology of intracranial tumors. Boston Med Surg J 1909; 141:71-80.
Nash CS. Cerebellar herniation as a cause of death. Ann Otol Rhinol Laryngol 1937; 46: 673-80.
VERBRUGGHEN A. Spinal puncture. Surg Clin North Am. 1946 Feb:78-90. No abstract available.
Munch EC, Bauhuf C, Horn P, Roth HR, Schmiedek P, Vajkoczy P. Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage. Crit Care Med. 2001 May;29(5):976-81. doi: 10.1097/00003246-200105000-00016.
Manet R, Payen JF, Guerin R, Martinez O, Hautefeuille S, Francony G, Gergele L. Using external lumbar CSF drainage to treat communicating external hydrocephalus in adult patients after acute traumatic or non-traumatic brain injury. Acta Neurochir (Wien). 2017 Oct;159(10):2003-2009. doi: 10.1007/s00701-017-3290-1. Epub 2017 Aug 8.
Murad A, Ghostine S, Colohan AR. A case for further investigating the use of controlled lumbar cerebrospinal fluid drainage for the control of intracranial pressure. World Neurosurg. 2012 Jan;77(1):160-5. doi: 10.1016/j.wneu.2011.06.018. Epub 2011 Nov 15.
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frolich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleo A, de Mendonca A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skarsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.
Song G, You Y, Jeong W, Lee J, Cho Y, Lee S, Ryu S, Lee J, Kim S, Yoo I. Vasopressor requirement during targeted temperature management for out-of-hospital cardiac arrest caused by acute myocardial infarction without cardiogenic shock. Clin Exp Emerg Med. 2016 Mar 31;3(1):20-26. doi: 10.15441/ceem.15.090. eCollection 2016 Mar.
Naito H, Isotani E, Callaway CW, Hagioka S, Morimoto N. Intracranial Pressure Increases During Rewarming Period After Mild Therapeutic Hypothermia in Postcardiac Arrest Patients. Ther Hypothermia Temp Manag. 2016 Dec;6(4):189-193. doi: 10.1089/ther.2016.0009. Epub 2016 May 23.
Sekhon MS, Griesdale DE, Ainslie PN, Gooderham P, Foster D, Czosnyka M, Robba C, Cardim D. Intracranial pressure and compliance in hypoxic ischemic brain injury patients after cardiac arrest. Resuscitation. 2019 Aug;141:96-103. doi: 10.1016/j.resuscitation.2019.05.036. Epub 2019 Jun 8.
Park JS, Cho Y, You Y, Min JH, Jeong W, Ahn HJ, Kang C, Yoo I, Ryu S, Lee J, Kim SW, Cho SU, Oh SK, Lee J, Lee IH. Optimal timing to measure optic nerve sheath diameter as a prognostic predictor in post-cardiac arrest patients treated with targeted temperature management. Resuscitation. 2019 Oct;143:173-179. doi: 10.1016/j.resuscitation.2019.07.004. Epub 2019 Jul 12.
Longstreth WT Jr, Nichol G, Van Ottingham L, Hallstrom AP. Two simple questions to assess neurologic outcomes at 3 months after out-of-hospital cardiac arrest: experience from the public access defibrillation trial. Resuscitation. 2010 May;81(5):530-3. doi: 10.1016/j.resuscitation.2010.01.011. Epub 2010 Feb 20.
Ameloot K, De Deyne C, Ferdinande B, Dupont M, Palmers PJ, Petit T, Eertmans W, Moonen C, Belmans A, Lemmens R, Dens J, Janssens S. Mean arterial pressure of 65 mm Hg versus 85-100 mm Hg in comatose survivors after cardiac arrest: Rationale and study design of the Neuroprotect post-cardiac arrest trial. Am Heart J. 2017 Sep;191:91-98. doi: 10.1016/j.ahj.2017.06.010. Epub 2017 Jun 23.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201907033003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.